Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

NCT04172454 PHASE1, PHASE2 COMPLETED

A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.

Details

Lead sponsor	Akeso
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	68
Start date	Fri Dec 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Sep 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Solid Tumors
• Melanoma

Interventions

• AK104

Countries

China